Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 studyMichel Attal, Michel Pavic, Xavier Leleu et al.|The Lancet|2019Cited by 635
Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)Niven Mehra, Johann S. de Bono, David Dolling et al.|European Urology|2018Cited by 110
Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNASemini Sumanasuriya, Johann S. de Bono, George Seed et al.|European Urology|2021Cited by 65